Silexion Therapeutics Potential IND/NDA Filing
Resolves: Company submits an Investigational New Drug (IND) application for a new indication or a New Drug Application (NDA) based on Phase 2 results.
sec_filing· Regulatory Filings
Silexion Therapeutics Potential IND/NDA Filing
Market overview
Derived from Silexion Therapeutics Corp (SLXN, SLXNW) (CIK 0002022416) 8-K filing analysis
Regulatory Filings prediction market
- Implied probability (Yes)
- 70%
- Closes
- 2027-06-30
About this prediction
Resolution criteria
Company submits an Investigational New Drug (IND) application for a new indication or a New Drug Application (NDA) based on Phase 2 results.
More Regulatory Filings markets
- Bitwise Bitcoin ETF 2026 Annual Filing — 95% Yes
- Timely Filing of 2026 10-K Report — 95% Yes
- Phase 3 Trial Initiation for KER-007 — 85% Yes
- Related Regulatory Filings — 40% Yes
- Post-Merger Regulatory Approvals — 60% Yes
- FDA approval for new drug candidate — 75% Yes
- Completion of Regulatory Filings for Acquisition — 85% Yes
- Phase 3 Interim Data Readout — 55% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…